Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA vaccine trial, despite reports swirling that Moderna’s own financial support ...
Hosted on MSN
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics
Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to ...
Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...
In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...
Arcturus has developed the first sa-mRNA COVID-19 vaccine, Kostaive, in the world. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative mRNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results